natgillin/translations-raw huggingface dataset:
Viracept has also been studied in 37 children. 
Zdravilo Viracept so raziskovali tudi pri 37 otrocih.
When the enzyme is blocked, the virus does not reproduce normally, slowing down the spread of infection. 
Ko je encim blokiran, se virus ne more več normalno razmnoževati, kar upočasni širjenje okužbe.
EPAR summary for the public nelfinavir 
Povzetek EPAR za javnost nelfinavir
Viracept should not be used in patients who are taking any of the following medicines: 
Zdravilo Viracept se ne sme uporabljati pri bolnikih, ki jemljejo katero koli od naslednjih zdravil:
• medicines that are broken down in the same way as Viracept and are harmful at high levels in the blood. 
• zdravila, ki se presnavljajo na enak način kot zdravilo Viracept in so pri visokih ravneh v krvi škodljiva.
For patients aged over 13 years, the recommended dose of Viracept is 1,250 mg twice a day or 750 mg three times a day, taken with food. 
Za bolnike, ki so starejši od 13 let, znaša priporočeni odmerek zdravila Viracept 1 250 mg dvakrat na dan ali 750 mg trikrat na dan s hrano.
For more information about treatment with Viracept, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Viracept preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Viracept. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Viracept, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The study in children showed that the medicine produced similar levels of the active substance in the blood in children and adults, with similar side effects and effectiveness. 
Študija pri otrocih je pokazala, da je zdravilo povzročilo podobne ravni zdravilne učinkovine v krvi otrok in odraslih ter podobne neželene učinke in učinkovitost.
The Committee and recommended that it be given marketing authorisation. 
Odbor je priporočil, da se za cepivo odobri dovoljenje za promet.
It blocks an enzyme called protease that is involved in the reproduction of HIV. 
Ta zavira encim, imenovan proteaza, ki sodeluje pri razmnoževanju virusa HIV.
Viracept does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS. 
Zdravilo Viracept ne zdravi okužbe z virusom HIV ali AIDS-a, lahko pa podaljša čas do pojava okvar imunskega sistema ter razvoja okužb in bolezni, ki so povezane z AIDS-om.
Viracept, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level. 
Zdravilo Viracept v kombinaciji z drugimi protivirusnimi zdravili zniža količino virusa HIV v krvi in jo vzdržuje na nizki ravni.
This is a summary of the European public assessment report (EPAR) for Viracept. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Viracept.
For patients unable to swallow the tablets, Viracept tablets may be dispersed in water or the oral powder may be used instead. 
Pri bolnikih, ki tablet ne morejo pogoltniti, se lahko tablete zdravila Viracept raztopijo v vodi ali pa se namesto tega uporabi peroralni prašek.
The main measures of effectiveness were the change in the levels of HIV in the blood (viral load) and the change in the number of CD4 T-cells in the blood (CD4 cell count). 
Glavni merili učinkovitosti sta bili sprememba ravni virusa HIV (virusne obremenitve) v krvi in sprememba števila T-celic CD4 v krvi.
CD4 cell counts increased by 150 and 95 cells/mm3, respectively. 
Pri obeh skupinah bolnikov se je povečalo tudi število celic CD4, in sicer za 150 oziroma 95 celic/mm3.
What benefit has Viracept shown during the studies? 
Kakšne koristi je zdravilo Viracept izkazalo med študijami?
• omeprazole (used to reduce stomach acid levels); 
• omeprazol (uporablja se za znižanje ravni želodčne kisline),
It is used in combination with other antiviral medicines to treat adults, adolescents and children over three years of age who are infected with human immunodeficiency virus (HIV-1), the virus that causes acquired immune deficiency syndrome (AIDS). 
Uporablja se v kombinaciji z drugimi protivirusnimi zdravili za zdravljenje odraslih, mladostnikov in otrok, starejših od 3 let, ki so okuženi z virusom humane imunske pomanjkljivosti 1 (HIV-1), ki povzroča sindrom pridobljene imunske pomanjkljivosti (AIDS).
Viracept, in combination with other antiviral medicines, was more effective than the comparator medicines in both main studies. 
Zdravilo Viracept v kombinaciji z drugimi protivirusnimi zdravili je bilo v obeh glavnih študijah učinkovitejše od primerjalnih zdravil.
Other information about Viracept 
Druge informacije o zdravilu Viracept
The most common side effect with Viracept (seen in more than 1 patient in 10) is diarrhoea. 
Najpogostejši neželeni učinek pri jemanju zdravila Viracept (opažen pri več kot 1 bolniku od 10) je driska.
In the second study, viral load had fallen by more than 99% in the patients taking the higher dose of Viracept, compared with 95% in those taking the comparator medicines. 
V drugi študiji se je virusna obremenitev bolnikov, ki so jemali višje odmerke zdravila Viracept, znižala za več kot 99 %, v primerjavi s 95 % pri tistih, ki so jemali primerjalna zdravila.
After 24 weeks, Viracept brought about greater reductions in viral load and increases in CD4 cell counts than the comparator medicines. 
Po 24 tednih je zdravilo Viracept bolj znižalo virusno obremenitev in povečalo število celic CD4 kot primerjalna zdravila.
See the package leaflet for the full list of these medicines. 
Za celoten seznam teh zdravil glejte navodilo za uporabo.
Viracept must not be used in people who are hypersensitive (allergic) to nelfinavir or any of the other ingredients. 
Zdravila Viracept ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) nelfinavir ali katero koli drugo sestavino zdravila.
There were no differences between the two doses of Viracept. 
Med obema načinoma odmerjanja zdravila Viracept ni bilo razlik.
Treatment with Viracept should be initiated by a doctor who has experience in the treatment of HIV infection. 
Zdravljenje z zdravilom Viracept lahko uvede le zdravnik, ki ima izkušnje z zdravljenjem okužbe z virusom HIV.
Viracept is an antiviral medicine. 
Viracept je protivirusno zdravilo.
Viracept has been studied in combination with other antiviral medicines in two main studies involving 605 patients aged 13 years or more, who were infected with HIV. 
Zdravilo Viracept v kombinaciji z drugimi protivirusnimi zdravili so raziskali v dveh glavnih študijah, ki sta vključevali 605 bolnikov, starih 13 let in več, ki so bili okuženi z virusom HIV.
What is the risk associated with Viracept? 
Kakšna tveganja so povezana z zdravilom Viracept?
Doctors should only prescribe Viracept to patients who have already taken medicines in the same class as Viracept (protease inhibitors) once they have looked at the antiviral medicines the patient has taken before and the likelihood that the virus will respond to the medicine. 
Zdravniki lahko zdravilo Viracept predpišejo le bolnikom, ki so že jemali zdravila iz istega razreda kot zdravilo Viracept (zaviralci proteaz), ko se seznanijo s protivirusnimi zdravili, ki jih je posameznik prejemal v preteklosti, in ocenijo verjetnost, da se bo virus odzval na zdravilo.
In the second study, Viracept, in combination with zidovudine and lamivudine (other antiviral medicines) was compared with the combination of zidovudine and lamivudine in 297 treatment-naïve patients (who had not taken any antiviral medicines to treat HIV infection before). 
V drugi študiji so zdravilo Viracept v kombinaciji z zidovudinom in lamivudinom (drugima protivirusnima zdraviloma) primerjali s kombinacijo zidovudina in lamivudina pri 297 bolnikih, ki se pred tem še niso zdravili zaradi okužbe s HIV.
In the first study, Viracept in combination with stavudine (another antiviral medicine) was compared with stavudine alone in 308 patients who had not taken stavudine or a protease inhibitor in the past. 
V prvi študiji so zdravilo Viracept v kombinaciji s stavudinom (drugim protivirusnim zdravilom) primerjali s stavudinom kot samostojnim zdravilom pri 308 bolnikih, ki v preteklosti še niso jemali stavudina ali zaviralcev proteaz.
Viracept brought about similar reductions in viral load whether it was taken twice or three times a day. 
Zdravilo Viracept je povzročilo podobna znižanja virusne obremenitve pri dvakratnem ali trikratnem jemanju na dan.
Three studies have compared the effectiveness of dosing Viracept twice and three times a day, in combination with stavudine and lamivudine in 635 patients. 
V treh študijah so pri 635 bolnikih primerjali učinkovitost odmerjanja zdravila Viracept v kombinaciji s stavudinom in lamivudinom dvakrat oziroma trikrat na dan.
Viracept is a medicine containing the active substance nelfinavir. 
Viracept je zdravilo, ki vsebuje zdravilno učinkovino nelfinavir.
Doctors should consider using alternatives to medicines that speed up the breakdown of Viracept, such as phenobarbital and carbamazepine (used to treat epilepsy), in patients taking Viracept. 
Pri bolnikih, ki jemljejo Viracept, morajo zdravniki razmisliti o uporabi alternativnih zdravil namesto zdravil, ki pospešujejo razgradnjo zdravila Viracept, kot sta fenobarbital ali karbamazepin (ki se uporabljata za zdravljenje epilepsije).
For the full list of all side effects seen with Viracept, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Viracept, glejte navodilo za uporabo.
Caution is needed when Viracept is taken at the same time as other medicines. 
Pri sočasnem jemanju zdravila Viracept z drugimi zdravili je potrebna previdnost.
Why has Viracept been approved? 
Zakaj je bilo zdravilo Viracept odobreno?
The active substance in Viracept, nelfinavir, is a protease inhibitor. 
Zdravilna učinkovina zdravila Viracept je nelfinavir, ki spada med zaviralce proteaz.
The CHMP decided that Viracept's benefits are greater than its risks in antiviral combination treatment of HIV-1 infected adults, adolescents and children of three years of age and older. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Viracept pri kombiniranem protiretrovirusnem zdravljenju odraslih, mladostnikov in otrok, starih 3 leta ali več, okuženih z virusom HIV-1, večje od z njim povezanih tveganj.
• St John's wort (a herbal preparation used to treat depression); 
• šentjanževko (rastlinski pripravek za zdravljenje depresije);
How has Viracept been studied? 
Kako je bilo zdravilo Viracept raziskano?
What is Viracept used for? 
Za kaj se zdravilo Viracept uporablja?
How is Viracept used? 
Kako se zdravilo Viracept uporablja?
Viracept should be used with caution in patients who have problems with their liver or kidneys. 
Bolniki s težavami z jetri ali ledvicami morajo zdravilo Viracept uporabljati previdno.
What is Viracept? 
Kaj je zdravilo Viracept?
How does Viracept work? 
Kako zdravilo Viracept deluje?
Aristo Pharma GmbH Wallenroder Strasse 8-10 D-13435 Berlin Germany 
Aristo Pharma GmbH Wallenroder Strasse 8-10 D-13435 Berlin Nemčija
(Invented) Name Strength Pharmaceutica l form 
(Izmišljeno) ime Jakost
Diotop 75 mg / 20 mg modified release hard capsules 
Diotop 75 mg/20 m g, trde kapsule s prirejenim sproščanjem
Protect from light. 
Zaščite pred svetlobo.
The events were most frequently reported during the first months on treatment. 
O teh učinkih so najpogosteje poročali v prvih mesecih zdravljenja.
You may then hear or feel a click. 
Ob tem lahko zaslišite ali začutite klik.
Appetite, energy intake and food choice 
Apetit, energijski vnos in izbira hrane
The mean duration of diabetes was 13.9 years. 
Povprečno trajanje sladkorne bolezni je bilo 13,9 leta.
Using the wrong medicine could cause severe harm to your health. 
Uporaba napačnega zdravila lahko zelo škoduje vašemu zdravju.
If you forgot to inject a dose and: 
Če ste pozabili injicirati odmerek in:
Atorvastatin Cmax was decreased by 38%. 
Cmax atorvastatina se je zmanjšala za 38 %.
• You should use this medicine once a week on the same day each week if possible. 
• To zdravilo morate uporabljati enkrat na teden, vedno na isti dan v tednu, če je le mogoče.
This is especially important if you have kidney problems. 
To je še posebej pomembno, če imate težave z ledvicami.
The treatment difference appeared early and persisted throughout the trial. 
Razlika v zdravljenju se je pojavila zgodaj in se je ohranila skozi celotno preskušanje.
Talk to your doctor for further information. 
Za dodatne informacije se posvetujte z zdravnikom.
Patients with event (%) 
Bolniki z dogodkom (%)
This was assessed not to be clinically relevant. 
Ocenili so, da to ni klinično pomembno.
The relevance for humans is considered to be low, but cannot be completely excluded. 
Pomen tega za človeka je domnevno majhen, a ga ni mogoče povsem izključiti.
Number of subjects at risk 
Število izpostavljenih tveganju
These patients should be monitored closely and treated according to clinical guidelines. 
Te bolnike je treba skrbno nadzirati in jih zdraviti v skladu s kliničnimi smernicami.
It is important that you drink plenty of fluids to prevent dehydration. 
Pomembno je, da pijete veliko tekočine in tako preprečite dehidracijo.
• if you are allergic to semaglutide or any of the other ingredients of this medicine (listed in section 6). 
• če ste alergični na semaglutid ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 08 February 2018 
Datum prve odobritve: 08. februar 2018
Your doctor will tell you how to treat low blood sugar and what to do if you notice these warning signs. 
Zdravnik vam bo povedal, kako zdraviti prenizek krvni sladkor in kaj storiti, če opazite te opozorilne znake.
This medicine is not an insulin and should not be used if: 
To zdravilo ni insulin in ga ne smete uporabljati:
Primary endpoint - MACE Components of MACE 
Primarni opazovani dogodek - MACE Elementi MACE
Needles and other waste material should be disposed of in accordance with local requirements. 
Igle in preostali odpadni material je treba zavreči v skladu z lokalnimi predpisi.
Check the flow 
Preverite pretok
• You can give yourself the injection at any time of the day - regardless of meals. 
• Zdravilo si lahko injicirate ob kateri koli uri, ne glede na obroke.
Detailed instructions for use are on the other side of this leaflet. 
Podrobni napotki so opisani na drugi strani tega navodila za uporabo.
This medicine is not recommended in children and adolescents under 18 years as the safety and efficacy in this age group have not yet been established. 
Uporaba tega zdravila ni priporočljiva za otroke in mladostnike, mlajše od 18 let, ker njegova varnost in učinkovitost v tej starostni skupini še nista bili dokazani.
This is normal, but you must still check the flow, if you use a new pen for the first time. 
To je normalno, vendar morate kljub temu preveriti pretok, ko nov injekcijski peresnik uporabite prvič.
The safety and efficacy of semaglutide in children and adolescents below 18 years have not yet been established. 
Varnost in učinkovitost semaglutida pri otrocih in mladostnikih, mlajših od 18 let, nista bili dokazani.
If you wish to become pregnant, you should stop using this medicine at least two months in advance. 
Če želite zanositi, morate to zdravilo prenehati uporabljati vsaj dva meseca prej.
Then inject your next dose as usual on your scheduled day. 
Nato injicirajte naslednji odmerek kot po navadi na vaš redni dan po urniku.
• change in the way food or drink tastes 
• spremenjen okus hrane ali pijač
Therefore, it is recommended to use contraception while using this medicine. 
Zato je priporočljivo, da med uporabo tega zdravila uporabljate kontracepcijo.
Postnatal growth and development were evaluated in cynomolgus monkeys. 
Postnatalno rast in razvoj so ocenili pri opicah cynomolgus.
once weekly 
enkrat na teden
In the event of overdose, appropriate supportive treatment should be initiated according to the patient's clinical signs and symptoms. 
V primeru prevelikega odmerjanja je treba začeti ustrezno podporno zdravljenje v skladu z bolnikovimi kliničnimi znaki in simptomi.
• severe allergic reactions (anaphylactic reactions). 
• hude alergijske reakcije (anafilaktične reakcije).
- In this case, you have not received any medicine - even though the dose counter has moved from the original dose that you have set. 
- V tem primeru niste prejeli nič zdravila, tudi če se je števec odmerka premaknil od začetnega odmerka, ki ste ga nastavili.
The day of weekly administration can be changed if necessary as long as the time between two doses is at least 3 days (>72 hours). 
Dan tedenskega odmerjanja je po potrebi mogoče spremeniti; pogoj za to je, da je presledek med dvema odmerkoma vsaj 3 dni (> 72 ur).
Whether these effects are related to the decreased maternal food consumption as a direct GLP-1 effect is unknown. 
Ali so bili ti učinki povezani z zmanjšanim uživanjem hrane pri samicah, kar je neposreden učinek GLP-1, ni znano.
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines, including herbal medicines or other medicines you bought without a prescription. 
Obvestite zdravnika, farmacevta ali medicinsko sestro, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo, vključno z zeliščnimi zdravili ali drugimi zdravili, ki ste jih kupili brez recepta.
In total 98% of the patients completed the trial and the vital status was known at the end of the trial for 99.6% of the patients. 
Skupaj je preskušanje dokončalo 98 % bolnikov in za 99,6 % bolnikov je bilo ob koncu preskušanja znano vitalno stanje.
• Turn the dose selector until the dose counter shows the flow check symbol ( 
• Vrtite izbirnik odmerka, dokler se na števcu odmerka ne pokaže simbol za preverjanje pretoka (
Higher body weight results in lower exposure; a 20% difference in body weight between individuals will result in an approximate 16% difference in exposure. 
Višja telesna masa zmanjša izpostavljenost; 20-odstotna razlika v telesni masi med posamezniki povzroči približno 16-odstotno razliko v izpostavljenosti.
You should seek immediate medical help and inform your doctor straight away if you get symptoms such as breathing problems, swelling of face and throat and a fast heartbeat. 
Nemudoma poiščite zdravniško pomoč in takoj obvestite zdravnika, če imate simptome, kot so težave z dihanjem, otekanje obraza in grla ter hiter srčni utrip.
Change the needle as described in step 5 ‘After your injection' and repeat all steps starting with step 1 ‘Prepare your pen with a new needle'. 
Iglo zamenjajte, kot je opisano v točki 5, "Po injiciranju", in ponovite vse korake, začenši s točko 1, "Pripravite injekcijski peresnik z novo iglo".
Avoid driving or using machines if you get any signs of low blood sugar. 
Ne vozite in ne upravljajte strojev, če imate kateri koli znak prenizkega krvnega sladkorja.
See step 2 ‘Check the flow'. 
Glejte točko 2, "Preverite pretok".
For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1. 
Za rezultate študij v zvezi s kombinacijami, učinki na urejenost glikemije in srčno-žilne dogodke ter skupinami bolnikov, ki so jih preučili, glejte poglavja 4.4, 4.5 in 5.1.
• you have type 1 diabetes - a condition where your body does not produce any insulin 
• če imate sladkorno bolezen tipa 1; bolezen, pri kateri vaše telo ne proizvaja insulina,
Weekly doses higher than 1 mg are not recommended. 
Tedenski odmerki, večji od 1 mg, niso priporočljivi.
In particular, tell your doctor, pharmacist or nurse if you are using medicines containing any of the following: 
Še zlasti morate zdravnika, farmacevta ali medicinsko sestro obvestiti, če uporabljate zdravila, ki vsebujejo kaj od naslednjega:
In 8 phase 3a trials 4,792 patients were exposed to semaglutide. 
V 8 preskušanjih faze 3a je bilo semaglutidu izpostavljenih 4.792 bolnikov.
Semaglutide is not a substitute for insulin. 
Semaglutid ni nadomestilo za insulin.
There were 158 events of new or worsening nephropathy. 
Opaženih je bilo 158 dogodkov novonastale nefropatije in poslabšanja nefropatije.
Rough handling or misuse may cause inaccurate dosing. 
Grobo ravnanje ali nepravilna uporaba lahko povzročita netočno odmerjanje.
Maximum concentration was reached 1 to 3 days post dose. 
Največja koncentracija je bila dosežena 1 do 3 dni po injiciranju odmerka.
If you become pregnant when using this medicine, talk to your doctor right away, as your treatment will need to be changed. 
Če med uporabo tega zdravila zanosite, se takoj posvetujte z zdravnikom, ker bo treba zdravljenje spremeniti.
• Do not inject Ozempic which has been exposed to direct sunlight. 
• Ne injicirajte zdravila Ozempic, ki je bilo izpostavljeno neposredni sončni svetlobi.
Semaglutide improves beta-cell function. 
Semaglutid izboljša delovanje celic beta.
This medicine should not be used during pregnancy, as it is not known if it may affect your unborn child. 
Tega zdravila ne smete uporabljati med nosečnostjo, ker ni znano, ali lahko škoduje nerojenemu otroku.
Severe and on-going stomach pain which could be due to acute pancreatitis If you have severe and on-going pain in the stomach area - see a doctor straight away as this could be a sign of acute pancreatitis (inflamed pancreas). 
Hude in dolgotrajne bolečine v trebuhu so lahko posledica akutnega pankreatitisa Če imate hude in dolgotrajne bolečine v trebuhu, se nemudoma posvetujte z zdravnikom, kajti lahko gre za znak akutnega pankreatitisa (vnetja trebušne slinavke).
These side effects can cause dehydration (loss of fluids). 
Ti neželeni učinki lahko povzročijo dehidracijo (izgubo tekočine).
The reactions are listed below by system organ class and absolute frequency. 
Učinki so navedeni spodaj glede na organski sistem in absolutno pogostnost.
Frequencies are defined as: very common: (≥1/10); common: (≥1/100 to <1/10); uncommon: (≥1/1,000 to <1/100); rare: (≥1/10,000 to <1/1,000) and very rare: (<1/10,000). 
Pogostnosti neželenih učinkov so opredeljene kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000) in zelo redki (< 1/10.000).
In each case, patients can then resume their regular once weekly dosing schedule. 
V vsakem primeru lahko bolniki nato nadaljujejo zdravljenje po ustaljenem urniku enkrat na teden.
See section 2, ‘Warning and precautions' for information on increased risk of low blood sugar and section 4 for the warning signs of low blood sugar. 
Glejte poglavje 2, podpoglavje "Opozorila in previdnostni ukrepi", za informacije o večjem tveganju za prenizek krvni sladkor in poglavje 4 za opozorilne znake prenizkega krvnega sladkorja.
Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. 
Semaglutid je analog GLP-1 s 94 % sekvenčno homologijo s človeškim GLP-1.
If you are pregnant or breast-feeding, think you might be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom, preden uporabite to zdravilo.
• reflux or heartburn - also called ‘gastro-esophageal reflux disease' (GERD) 
• refluks ali zgaga; to imenujemo tudi "gastroezofagealna refluksna bolezen (GERB)"
Do not use this medicine after the expiry date which is stated on the pen label and carton after 'EXP'. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki injekcijskega peresnika in na škatli poleg oznake "EXP".
The injection site can be changed without dose adjustment. 
Mesto injiciranja je mogoče spreminjati brez prilagoditve odmerka.
Decreased appetite 
zmanjšanje apetita